Helping clinical teams create 'hospital at home' services for an episode of care with a specific time frame. This prevents unnecessary admissions and readmissions, cancellations and supports discharge and rehabilitation.
Our 'hospital at home' provides care throughout the perioperative pathway.
Patients are prepared for their surgery using timely educational content, questionnaires, symptom and activity tracking, alongside telemedicine.
After surgery patients are monitored remotely to guide their rehabilitation. Clinical teams gather aggregated, anonymised data to study and learn from the outcomes of surgery for each type of implant, surgical technique and approach to rehabilitation.
"The app is a major development which we believe will make an immediate impact on the surgical landscape."
length of stay
of respondents said
the Huma app was
easy to use1
We are working with clinicians at Royal Brompton and Harefield hospitals to help clinicians safely and efficiently manage patients who are waiting for surgery. Our technology is just one way the clinical teams are working with their patients, but it gives them greater ability to remotely monitor patients and identify any who need further intervention.
Patients successfully onboarded2
of patients identified as
at-risk of deterioration
of patients highlighted as
deteriorating had operation
dates brought forward3
Huma is currently working with Bayer, Stanford Medicine and the Stanford Center for Digital Health (CDH) to validate an approach to decentralize the clinical trial experience for patient participants with atrial fibrillation. The study aims to prove the feasibility, acceptability, and best practices that can achieve high compliance, quality, and scientifically sound fully remote clinical trials.
94% of participants
recruited in 12 days4
Increased oral anticoagulation adherence from 85% to 96% in patients with low baseline adherence4
Huma’s ‘hospital at home’ service for COVID-19 allows clinicians to remotely monitor their patients via their smartphones.
Our technology has shown to almost double clinical capacity, reduce readmissions, improve patient experience, and save money. Operating at a national-level across England, Germany and the UAE.
"I got all the monitoring of a hospital ward, right here at home."
can reduce readmission
rate by >30%1
can almost double
of patients reported ‘good’
or ‘very good’ care1
90% reported the app as
‘good’ or ‘very good’1
CEO & Founder Dan Vahdat speaks at World Economic Forum event in Davos.
Tamer will bring Huma’s ‘hospitals at home’ technology to the Kingdom of Saudi Arabia to tackle diabetes and cardiovascular disease.
Huma has won the Prix Galien International 2022 ‘best of the best digital health product’ award for the impact of its remote patient monitoring platform across healthcare and research.
Huma’s Nico O'Kuinghttons discusses how we can drive more efficient decentralized and hybrid clinical trials post-pandemic
Learn how Huma’s technology helps clinicians improve outcomes for heart failure patients and identify deteriorating cardiac surgery patients with almost 90% specificity.
Huma researchers have verified a way to measure breathing rate using the gyroscopes in entry-level smartphones.
Huma joined leading industry experts for a Reuters Events webinar on fostering diversity in decentralized and hybrid clinical trials
Huma acquires AstraZeneca’s digital health platform AMAZE™ and AstraZeneca becomes a shareholder of Huma
Huma and iPLATO (myGP) hosted a joint webinar on how we can bring digital-first care to patients at scale
How digital-first care and research can address the gender bias in cardiovascular disease
A new remote care monitoring system for patients suffering from chronic conditions
Huma & iPLATO (myGP) join to create new possibilities in healthcare and research
How we’re helping ~two million users across our platforms and people around the world live longer, fuller lives
The two companies will combine their expertise to provide remote patient monitoring for NHS patients
We launched a 12-week remote patient monitoring pilot with Cwm Taf and Betsi Cadwaladr University Health Boards
Sharif joins Huma to lead business development activities for digital companion app product
Huma’s ‘hospital at home’ technology will expand care capacity in Pune, India by up to 60%
Our peer-reviewed research explored the link between time of sleep and risk of cardiovascular disease in over 88,000 people
Accelerometer-derived sleep onset timing and cardiovascular disease incidence: a UK Biobank cohort study
Taking the "clinic" out of clinical trials and healthcare: Bridging research and care with digital tools
Huma’s remote patient monitoring technology is awarded ‘pharma’s Nobel Prize’
How digital technology is helping to battle the growing waiting list backlog
Medical technology powered using artificial intelligence
Our teams enabled better patient care and doubled clinical capacity with our hospital at home technology.
Our research was published in European Heart Journal Digital Health (EHJ-DH)
Peer-reviewed research published in Nature Scientific Reports
Machine learning approach to dynamic risk modeling of mortality in COVID-19: a UK Biobank cohort study
Development of digitally obtainable 10-year risk scores for depression and anxiety in the general population
We worked with Royal Brompton and Harefield hospitals to remotely monitor and prioritise deteriorating patients.
Implementation of an mHealth solution to remotely monitor patients on a cardiac surgical waiting list: Feasibility Study
Development of an accessible 10-year Digital CArdioVAscular (DiCAVA) risk assessment: a UK Biobank study
In an interview with Sky News today, Dan Vahdat describes how the new investment will support our mission to help people live longer and fuller lives.
We were drawn to Huma’s mission to power individualised healthcare outside of a traditional hospital.
Leading names in health and technology fund expansion
Including Bayer, Hitachi, Samsung, Sony Innovation Fund by IGV, Unilever & the PE fund HAT.
Press release: RARE-X’s federated data platform will pair with Huma’s DCT platform to accelerate research
Listen to and share our first webinar on-demand.
Watch our webinar with leaders from the NHS and the AHSH Network.
Press release: Huma listed in the Top 25 for all sectors
Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis
Press release: Smith+Nephew and Huma develop RPM app to assist the restart of UK orthopaedic surgery
Press release: German states focus on patient care via app
Three important lessons on how COVID-19 is shaping modern medicine
Exploring the Effects of a Brief Biofeedback Breathing Session Delivered Through the BioBase App in Facilitating Employee Stress Recovery: Randomized Experimental Study
Medopad rebrands and acquires two tech companies to bolster remote monitoring of patients
Efficacy of the Digital Therapeutic Mobile App BioBase to Reduce Stress and Improve Mental Well-Being Among University Students: Randomized Controlled Trial
Development and validation of risk scores for all-cause mortality for the purposes of a smartphone-based ‘general health score’ application: a prospective cohort study using the UK Biobank
Medopad and Janssen develop digital test to detect and quantify Alzheimer's Disase progression.
I feel it in my finger: Measurement device affects cardiac interoceptive accuracy
A computationally efficient algorithm to obtain an accurate and interpretable model of the effect of circadian rhythm on resting
A novel non-invasive cuff-less optoelectronic sensor to measure blood pressure comparison against intra-arterial measurement.
Analysis of the Impact of Interpolation Methods of Missing RR-intervals Caused by Motion Artifacts on HRV Features Estimations
Medopad and Tencent expands partnership to develop cutting edge AI and predictive capabilities for Psoriasis, MS, Cardiovascular disease and more.
Designing meaningful outcome parameters using mobile technology: a new mobile application for telemonitoring of patients with heart failure
Medopad acquires patient-tracking rival Sherbit to expand to US and boost AI capabilities.
China to test data monitoring system for hospital outpatients under trial scheme this year
BOAO Conference 2018: How technology can keep patients with chronic conditions away from hospitals
Healthtech startup without VC funding lands $140 in Chinese deals and partnership with Tencent
Profiling the propagation of error from PPG to HRV features in a wearable physiological-monitoring device
Tim Cook, CEO of Apple, references Medopad’s Aple Watch patient monitoring app and work with London King’s College Hospital in his Q3 earnings
The Association between Work-Related Rumination and Heart Rate Variability: A Field Study
A method and systems to create sonification of biological signals for user interaction purposes. (Granted)
Monitoring a change in a neurodegenerative disease in a user (Pending)
A method and systems to implement a device that gives the user feedback on breathing exercises to elicit the relaxation response using ECG. (Granted)
A method to fit HR data to the expected shape of the circadian rhythm. (Pending)
A method to exploit the shape of PPG data from bands affected by motion artifacts. (Pending)
Method for characterising data representing characteristics of a user’s gait at different points in time (Pending)
Monitoring the change in a neurodegenerative disease in a user (Pending)
Non-invasive blood pressure monitoring system and method for providing continuous, "beat-to-beat" measures of blood pressure (Published)
Method for sensing an arterial pulse (22 granted, 3 published)
A method to unify several physiology and psychology data variables into an overall mental wellbeing score. (Pending)
The full report is available on request. Patient feedback based on sample size of 30 responses.
2. Data correct as of October 2021.
3. Obika, BD et al. (2021) Implementation of a mHealth solution to remotely monitor patients on a cardiac surgical waiting list: service evaluation JAMIA Open 4(3) doi.org/10.1093/jamiaopen/ooab053
4. Data from 2021 single-arm, six-month study. Paper in submission.